摘要
目的探讨非霍奇金淋巴瘤(NHL)患者外周血淋巴细胞(PBLC)的DNA修复率(DRR)与含烷化剂联合化疗疗效的关系。方法采用单细胞凝胶电泳法检测30例NHL患者(肿瘤组)PBLC的DRR,并选取20例非肿瘤患者作对照(对照组)。肿瘤组接受含环磷酰胺联合方案化疗并于4个周期后评价疗效,分析肿瘤组和对照组PBLC在环磷酰胺暴露前与暴露且修复后的DRR水平,同时分析肿瘤组DRR与临床病理特征及含烷化剂联合化疗疗效的关系。结果利用尾长(TL)(Z=4.464,P=0.000)和尾相(TM)(Z=3.828,P=0.000)检测肿瘤组PBLC的DRR均低于对照组(P<0.05)。肿瘤组PBLC的DRR与年龄、性别、ECOG评分、临床分期、LDH值、Ki-67增殖指数和是否饮酒均无关(P>0.05)。30例NHL患者中获CR 4例、PR 14例、SD 10例和PD 2例,有效率为60.0%,疾病控制率为93.3%。以TL评价DRR提示DRR与化疗疗效呈负相关(r=-0.409,P=0.025),以TM评价DRR提示DRR与化疗疗效无关(r=-0.224,P=0.234)。结论 NHL患者较非肿瘤患者DNA修复能力降低;DRR与NHL患者含烷化剂联合化疗近期疗效呈负相关。
Objective To investigate the relationship between DNA repair rate（ DRR） of peripheral blood lymphocyte（ PBLC） and the efficacy of combination chemotherapy containing alkylating agents for NHL patients. Methods The DRRs of PBLC in30 patients with NHL and 20 controls without cancer were detected by single cell gel electrophoresis（ SCGE）. The NHL patients received chemotherapy including cyclophosphamide and the efficacy was evaluated after four cycles. In both groups,the DRRs before cyclophosphamide exposure and after exposure followed by restoration were analyzed. The correlation between the DRR of NHL group and the clinicopathological features as well as the efficacy of combined chemotherapy containing alkylating agents was investigated. Results DRRs of the NHL patients were obviously lower than the controls by tail length（ Z = 4. 464,P = 0. 000） and tail moment（ Z = 3. 828,P = 0. 000）. The DRRs have no relationship with age,gender,ECOG score,clinical stage,LDH value,Ki-67 proliferation index and drinking habits（ P〉0. 05）. As for 30 NHL patients,there were CR in 4 cases,PR in 14 cases,SD in 10 cases and PD in 2 cases with response rate of 60. 0% and disease control rate of 93. 3%. To evaluate DRRs with tail length（ r =-0. 409,P = 0. 025）,it showed that DRRs were negatively correlated with the efficacy of chemotherapy. In addition,no relationship was found between DRRs and efficacy by tail moment（ r =-0. 224,P = 0. 234）. Conclusion NHL patients have lower DNA repair capacity than people without cancer. The DRR in PBLCs is correlated negatively with the efficacy of NHL patients treated with alkylating agents.
出处
《临床肿瘤学杂志》
CAS
2016年第6期514-518,共5页
Chinese Clinical Oncology
关键词
非霍奇金淋巴瘤
外周血淋巴细胞
DNA修复
烷化剂
Non-Hodgkin＇s lymphoma（NHL）
Peripheral blood lymphocyte（PBLC）
DNA repair
Alkylating Agent
